CDH1 Gene Hereditary Diffuse Gastric Cancer NGS Genetic DNA Test
Understanding Hereditary Diffuse Gastric Cancer and CDH1 Gene Testing
Hereditary Diffuse Gastric Cancer (HDGC) is a rare but aggressive form of stomach cancer that runs in families due to specific genetic mutations. The CDH1 gene plays a critical role in this hereditary condition, as mutations in this gene significantly increase an individual’s lifetime risk of developing diffuse gastric cancer. Our comprehensive NGS genetic DNA test provides advanced screening capabilities to identify these mutations early, enabling proactive health management and potentially life-saving interventions.
What Does the CDH1 Gene Test Measure?
This sophisticated genetic test utilizes Next-Generation Sequencing (NGS) technology to thoroughly analyze the CDH1 gene for pathogenic variants. The test specifically detects:
- Point mutations and small insertions/deletions in the CDH1 gene
- Genetic variations associated with hereditary diffuse gastric cancer syndrome
- Inherited mutations that significantly increase gastric cancer risk
- Genetic markers for lobular breast cancer, which is also associated with CDH1 mutations
Who Should Consider CDH1 Genetic Testing?
This test is particularly recommended for individuals who meet any of the following criteria:
- Family history of diffuse gastric cancer in two or more first or second-degree relatives
- Personal or family history of lobular breast cancer before age 50
- Individuals with CDH1 mutation-positive relatives
- Patients diagnosed with diffuse gastric cancer before age 40
- Those with multiple family members affected by gastric or breast cancers
- Individuals of Maori descent with family history of gastric cancer
Clinical Symptoms and Risk Factors
While hereditary diffuse gastric cancer may not present obvious early symptoms, individuals should be aware of potential warning signs including unexplained weight loss, persistent abdominal discomfort, difficulty swallowing, early satiety, and nausea. However, it’s crucial to understand that HDGC often develops without noticeable symptoms until advanced stages, making genetic testing particularly valuable for at-risk individuals.
Benefits of CDH1 Genetic Testing
Undergoing CDH1 genetic testing provides numerous significant advantages:
- Early Risk Assessment: Identify genetic predisposition before cancer develops
- Personalized Screening: Implement targeted surveillance protocols based on genetic status
- Family Planning: Make informed reproductive decisions with genetic counseling
- Preventive Options: Consider prophylactic measures for high-risk individuals
- Peace of Mind: Reduce uncertainty through definitive genetic information
- Comprehensive Care: Access specialized medical management and support services
Understanding Your Test Results
Your CDH1 genetic test results will fall into one of three categories, each with specific implications:
Positive Result
A positive result indicates the presence of a pathogenic CDH1 mutation. This means you have an inherited predisposition to hereditary diffuse gastric cancer, with lifetime risks estimated at 56-70% for men and 42-83% for women. Positive results should be discussed with a genetic counselor and oncology specialist to develop a personalized management plan, which may include enhanced surveillance or preventive surgery.
Negative Result
A negative result means no pathogenic CDH1 mutations were detected. However, this doesn’t completely eliminate cancer risk, as other genetic or environmental factors may contribute. Regular cancer screening according to general population guidelines remains important.
Variant of Uncertain Significance (VUS)
Sometimes, the test identifies genetic changes whose clinical significance is unknown. These variants require ongoing monitoring as research evolves. Your genetic counselor will provide guidance on appropriate follow-up and family testing recommendations.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | CDH1 Gene Hereditary Diffuse Gastric Cancer NGS Genetic DNA Test |
| Regular Price | $700 USD |
| Discount Price | $500 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) |
| Specialty | Oncology Genetics |
Pre-Test Requirements
Before undergoing CDH1 genetic testing, we recommend:
- Comprehensive clinical history documentation
- Genetic counseling session with certified genetic counselor
- Development of detailed family pedigree chart
- Discussion of potential outcomes and implications
- Informed consent process
Nationwide Testing Availability
We proudly offer CDH1 genetic testing services across the United States, with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Jacksonville, Fort Worth, Columbus, San Francisco, and many more. Our network of certified collection centers ensures accessible testing for patients nationwide.
Take Control of Your Genetic Health Today
Don’t let uncertainty about your genetic risk for hereditary diffuse gastric cancer impact your health decisions. Our CDH1 genetic test provides the clarity and information needed to make empowered healthcare choices. With advanced NGS technology and comprehensive analysis, you can gain valuable insights into your genetic predisposition and take proactive steps toward cancer prevention and early detection.
Ready to schedule your CDH1 genetic test? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Our team is available to answer your questions, provide detailed information about the testing process, and help you take the next step toward understanding your genetic health.
Early detection through genetic testing can be life-saving. Take the first step toward comprehensive cancer risk assessment and personalized health management by scheduling your CDH1 genetic test today.
